Tag Archives: kaufman

Chemotherapy: Greater potential benefit in overall survival for eribulin compared with capecitabine

The specific patient populations who appeared to benefit from eribulin, in comparison to capecitabine, are as follows: Patients with more than two organs involved with metastatic breast cancer Patients who had not received chemotherapy for six months or longer Patients who had received anthracycline and/or a taxane therapies in the metastatic setting Previous pre-specified exploratory analysis of overall survival and progression-free survival showed women with triple-negative, ER-negative, HER2-negative also had a greater relative benefit in overall survival with eribulin over capecitabine. …